Advances in Statistical Approaches Oncology Drug Development.

about

Advances in Statistical Approaches Oncology Drug Development.

Item

http://www.wikidata.org/entity/Q35565672

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Advances in Statistical Approaches Oncology Drug Development.

@ast

Advances in Statistical Approaches Oncology Drug Development.

@en

type

Item

label

Advances in Statistical Approaches Oncology Drug Development.

@ast

Advances in Statistical Approaches Oncology Drug Development.

@en

prefLabel

Advances in Statistical Approaches Oncology Drug Development.

@ast

Advances in Statistical Approaches Oncology Drug Development.

@en

P1476

Advances in Statistical Approaches Oncology Drug Development.

@en

P2093

Anastasia Ivanova

http://www.w3.org/2001/XMLSchema#string

Gary L Rosner

http://www.w3.org/2001/XMLSchema#string

Inna Perevozskaya

http://www.w3.org/2001/XMLSchema#string

Olga Marchenko

http://www.w3.org/2001/XMLSchema#string

Tom Parke

http://www.w3.org/2001/XMLSchema#string

Yanping Wang

http://www.w3.org/2001/XMLSchema#string

P2860

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Designs for single- or multiple-agent phase I trials.

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Bayesian design of single-arm phase II clinical trials with continuous monitoring.

Admissible two-stage designs for phase II cancer clinical trials.

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.

A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer

Bayesian optimal design for phase II screening trials

P304

81-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2168479013501309

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25949927

http://www.w3.org/2001/XMLSchema#string

P932

4418493

http://www.w3.org/2001/XMLSchema#string